Zobrazeno 1 - 10
of 158
pro vyhledávání: '"Frederic I, Preffer"'
Publikováno v:
Cytometry Part B: Clinical Cytometry. 98:299-327
Chimeric antigen receptor (CAR) T cells provide a promising approach to the treatment of hematologic malignancies and solid tumors. Flow cytometry is a powerful analytical modality, which plays an expanding role in all stages of CAR T therapy, from l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5529ee3c78a3c646990e6361497ac09c
https://doi.org/10.1002/cyto.b.21880
https://doi.org/10.1002/cyto.b.21880
Autor:
Rupa Narayan, Robert P. Hasserjian, Margaret C. Wey, Tanya T. Behnan, Meghan Bergeron, Jessica Rae, Mason L. Mann, Ashkan Emadi, Christina Bertoli, Eyal C. Attar, Traci M. Blonquist, Christopher Lescinskas, Jenna A. Moran, Yi-Bin Chen, Steven L. McAfee, Vu H. Duong, Patricia Lesho, Timothy A. Graubert, Jennifer Lombardi Story, Andrew M. Brunner, Meghan Burke, Megan K. Vartanian, Gabriela S. Hobbs, Tina T. Som, Donna Neuberg, Hanno Hock, Molly Macrae, Julia Foster, Kristin McGregor, Philip C. Amrein, Amir T. Fathi, Karen K. Ballen, Frederic I. Preffer, Aura Y. Ramos, Christine Connolly
Publikováno v:
Cancer. 126:1264-1273
Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody-drug conjugate that is specific for human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::411429856bce3fe963798cabff48aa70
https://doi.org/10.1002/cncr.32657
https://doi.org/10.1002/cncr.32657
Autor:
Frederic I. Preffer
Publikováno v:
Cytometry Part B: Clinical Cytometry. 98:461-463
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c7b5fda411ca51aa57b6700a0eb2292
https://doi.org/10.1002/cyto.b.21972
https://doi.org/10.1002/cyto.b.21972
Autor:
Frederic I. Preffer
Publikováno v:
Cytometry. Part B, Clinical cytometry. 100(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28f4cc094264ea45e9b31f4cebb0f3c7
https://pubmed.ncbi.nlm.nih.gov/32830879
https://pubmed.ncbi.nlm.nih.gov/32830879
Autor:
Matthew J. Frigault, Scott J. Rodig, Alexandra J. Shay, Ana P. Castano, Alexandria Van Scoyk, Maria Ormhøj, Frederic I. Preffer, David M. Weinstock, Irene Scarfò, Jon C. Aster, Marcela V. Maus, Selena J. Lorrey, Amanda A. Bouffard
Publikováno v:
Scarfò, I, Ormhøj, M, Frigault, M J, Castano, A P, Lorrey, S, Bouffard, A A, Van Scoyk, A, Rodig, S J, Shay, A J, Aster, J C, Preffer, F I, Weinstock, D M & Maus, M V 2018, ' Anti-CD37 chimeric antigen receptor T cells are active against B-A nd T-cell lymphomas ', Blood, vol. 132, no. 14, pp. 1495-1506 . https://doi.org/10.1182/blood-2018-04-842708
Chimeric antigen receptor (CAR) T cells have emerged as a novel form of treatment of patients with B-cell malignancies. In particular, anti-CD19 CAR T-cell therapy has effected impressive clinical responses in B-cell acute lymphoblastic leukemia and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d91e070166ddd44bc22ffe5a37c72ed2
https://doi.org/10.1182/blood-2018-04-842708
https://doi.org/10.1182/blood-2018-04-842708
Autor:
Frederic I. Preffer
Publikováno v:
Cytometry Part B: Clinical Cytometry. 96:9-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cb7ab006ac42fc6d3b87a553e114888
https://doi.org/10.1002/cyto.b.21762
https://doi.org/10.1002/cyto.b.21762
Autor:
Kit L. Shaw, Irene Scarfò, Lu Huang, Thomas R. Spitzer, Areej El-Jawahri, Steven L. McAfee, Matthew J. Frigault, Frederic I. Preffer, Kathleen Gallagher, Heather Daley, Nora Horick, Myriam Armant, Marcela V. Maus, Jerome Ritz, Daniella Cook, Keagan S Casey, Sarah Nikiforow, Yi-Bin Chen, Marc Wehrli
Publikováno v:
Blood. 138:653-653
Background: CD37 is a tetraspanin molecule expressed in B-cell and some T-cell lymphomas. We designed a Chimeric Antigen Receptor (CAR) targeting CD37 and with 4-1BB and CD3z intracellular signaling domains (CART37). Preclinical studies indicated com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::974b7f12e9dfe9d6d3ea966dc191309f
https://doi.org/10.1182/blood-2021-146236
https://doi.org/10.1182/blood-2021-146236
Autor:
Joren C. Madsen, M. J. O’Neil, K.S. Mordecai, G. La Muraglia, Frederic I. Preffer, I.M. Hanekamp, Maria Lucia Madariaga, James S. Allan, Sebastian Michel
Publikováno v:
Journal of Immunological Methods. 427:85-93
In this study, we established a novel isotope-free approach for the detection of cell-mediated lympholysis (CML) in MHC defined peripheral blood mononuclear cells (PBMCs) using multiparameter flow and imaging cytometry. CML is an established in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa8bbfb3768cab945d4a4b2c36ca9fd
https://doi.org/10.1016/j.jim.2015.10.005
https://doi.org/10.1016/j.jim.2015.10.005
Autor:
Arthur S. Grove, Nancy L. Harris, Vikram Deshpande, Veronica E. Klepeis, Frederic I. Preffer, Judith A. Ferry, John H. Stone, Aliyah R. Sohani
Publikováno v:
American Journal of Surgical Pathology. 39:1688-1700
Although chronic inflammatory disorders of the ocular adnexa are relatively common, their pathogenesis is in many cases poorly understood. Recent investigation suggests that many cases of sclerosing orbital inflammation are a manifestation of IgG4-re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc995567834183d8bac27dd99ceb4056
https://doi.org/10.1097/pas.0000000000000497
https://doi.org/10.1097/pas.0000000000000497
Autor:
David R. Bangsberg, Bimalangshu R. Dey, Jason Harlow, Akhil Ranjan Biswas, Jenna A. Moran, Mark Brezina, Frederic I. Preffer, Martin Caron, Kamruzzaman, Ariela L. Marshall, Mafruha Akter, Eyal C. Attar, Salma Afrose, Manirul Islam, Anup Saha, Tasneem Ara, Anne-Marie Barron, Annekathryn Goodman, Christopher P. Stowell, Albert C. Yeh, Jannatul Ferdous, Thomas R. Spitzer, Steven L. McAfee, Humayra Nazneen, Mohiuddin Ahmed Khan
Publikováno v:
Journal of Global Oncology
Journal of Global Oncology, Vol 4, Pp 1-10 (2016)
Journal of Global Oncology, Vol 4, Pp 1-10 (2016)
Purpose Treatment of malignant and nonmalignant hematologic diseases with hematopoietic stem-cell transplantation (HSCT) was first described almost 60 years ago, and its use has expanded significantly over the last 20 years. Whereas HSCT has become t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfddb2a8c7a2aa293712df0b711a036f
https://pubmed.ncbi.nlm.nih.gov/30241180
https://pubmed.ncbi.nlm.nih.gov/30241180